At a Glance
| Item | Detail |
|---|---|
| CDL / PMB Status | Chronic Disease List (CDL) condition |
| ICD-10 Codes | J44.0–J44.9 |
| SA Prevalence | ~9% of adults (~4–5 million people) |
| Annual Cost (managed — GOLD 1–2) | R4,800–R15,000 |
| Annual Cost (severe — GOLD 3–4) | R15,000–R85,000 |
| Biologic Risk | No (biologic-adjacent: dupilumab emerging) |
| Gap Cover Relevance | High |
What is COPD?
Chronic Obstructive Pulmonary Disease (COPD) is a progressive, irreversible lung disease characterised by persistent airflow limitation. Unlike asthma, airflow obstruction in COPD is not fully reversible and worsens over time. COPD is primarily caused by long-term exposure to harmful particles or gases — in South Africa, cigarette smoking is the dominant cause, but indoor biomass fuel combustion (cooking fires, paraffin stoves) is a significant additional risk factor in rural communities.
COPD encompasses two main patterns: chronic bronchitis (persistent cough with mucus production) and emphysema (destruction of alveolar walls with loss of elastic recoil). Most patients have a mixture of both. The condition is severely under-diagnosed in South Africa — it is estimated that only 30–40% of COPD patients receive a formal diagnosis.
COPD is a Chronic Disease List (CDL) condition. It is the third leading cause of death globally and a major driver of hospitalisation costs in SA.
GOLD Classification of Severity
Severity is measured by spirometry — the FEV1 (forced expiratory volume in 1 second) as a percentage of predicted normal:
| GOLD Grade | FEV1 % Predicted | Description |
|---|---|---|
| GOLD 1 (Mild) | ≥ 80% | Minimal symptoms; may be undiagnosed |
| GOLD 2 (Moderate) | 50–79% | Breathlessness on exertion; increasing limitation |
| GOLD 3 (Severe) | 30–49% | Significant impairment; frequent exacerbations |
| GOLD 4 (Very Severe) | < 30% | Severe breathlessness at rest; home oxygen may be required |
Most SA patients are first diagnosed at GOLD 2 or 3 when symptoms are undeniable.
How is COPD Treated?
There is no cure for COPD. Treatment is aimed at symptom relief, preventing exacerbations, slowing progression, and improving quality of life. Smoking cessation is the single most effective intervention and slows disease progression at any stage.
Step 1 — Reliever + smoking cessation: - SABA (Short-acting beta-agonist): Salbutamol (Ventolin) — for on-demand relief of breathlessness. ~R80/month. - Smoking cessation: Varenicline (Champix) or nicotine replacement — may be covered by some schemes; significantly reduces exacerbation rate and hospitalisation.
Step 2 — Long-acting bronchodilators (GOLD 2+): - LAMA (Long-acting muscarinic antagonist): Tiotropium (Spiriva) — once daily inhaler; reduces breathlessness and exacerbation frequency. ~R650/month. The cornerstone of COPD maintenance therapy. - LABA/ICS combination: Salmeterol/fluticasone (Seretide/generic) or formoterol/budesonide — for patients with exacerbations or eosinophilia. ~R600–R700/month.
Step 3 — Triple therapy (GOLD 3–4): - LABA + LAMA + ICS: Umeclidinium/vilanterol/fluticasone (Trelegy) or formoterol/glycopyrronium/budesonide (Trixeo). ~R1,400/month. Most effective regimen for preventing exacerbations in severe COPD.
Add-on therapies for very severe COPD: - Roflumilast (Daxas — PDE4 inhibitor): For GOLD 3–4 with chronic bronchitis phenotype and ≥ 2 exacerbations/year. ~R1,200/month. - Home oxygen therapy: For GOLD 4 with resting SpO2 < 88%. Some schemes fund home oxygen concentrators; verify per scheme. - Pulmonary rehabilitation: Structured exercise and education programme — the most cost-effective intervention after medication for GOLD 2+. Reduces hospitalisations.
Medication Costs (2025/2026 — Prices Estimated; SAHPRA SEP Verification Pending)
| Medication | Class | Monthly Cost | Annual Cost |
|---|---|---|---|
| Salbutamol inhaler (SABA) | Reliever | ~R80 | ~R960 |
| Tiotropium (Spiriva Respimat) | LAMA maintenance | ~R650 | ~R7,800 |
| Salmeterol/fluticasone (LABA/ICS) | Combination maintenance | ~R700 | ~R8,400 |
| Umeclidinium/vilanterol/fluticasone (Trelegy) | Triple therapy | ~R1,400 | ~R16,800 |
| Roflumilast (Daxas) | PDE4 inhibitor (add-on) | ~R1,200 | ~R14,400 |
Annual Cost Breakdown
| Category | Low Estimate (GOLD 1–2) | High Estimate (GOLD 3–4) |
|---|---|---|
| GP visits (4 per year) | R3,200 | R3,200 |
| Pulmonologist (2 per year) | R3,000 | R6,000 |
| Chronic medication | R7,800 | R16,800 |
| Monitoring (spirometry, O2 sat, flu vaccine, CXR) | R2,000 | R4,000 |
| Hospital (AECOPD admission) — moderate probability | R0 | R60,000 |
| Total estimated annual cost | ~R16,000 | ~R90,000 |
Medical Aid Coverage
COPD is a CDL condition. Registered schemes must cover: - Bronchodilators (SABA, LAMA, LABA/ICS) at CDL formulary level - Pulmonologist consultations and GP management - Spirometry (diagnostic and annual monitoring) - Influenza and pneumococcal vaccination (recommended annually) - AECOPD emergency treatment (PMB emergency)
Formulary note: Triple therapy (Trelegy) and roflumilast are higher-cost agents that may require pre-authorisation or exceptional needs motivation on some scheme formularies.
Home oxygen: Coverage varies significantly by scheme. Check whether your scheme funds home oxygen concentrators for GOLD 4 patients with persistent hypoxaemia.
Gap Cover Relevance
High — driven by acute COPD exacerbation hospitalisation. AECOPD is the major financial event. A moderate AECOPD requiring 2–4 days hospitalisation with pulmonologist management costs R15,000–R40,000. A severe exacerbation requiring HDU or ICU and ventilatory support can reach R60,000+.
Gap cover use cases for COPD: - Pulmonologist shortfall on in-hospital visits - ICU/HDU specialist (intensivist) shortfall - Hospital co-payment above scheme rate - Surgical shortfall for bullectomy or lung volume reduction surgery (rare, very severe emphysema)
Note: The gap cover annual overall payment limit is approximately R220,000. For a single severe AECOPD with ICU admission, multiple specialist shortfalls may accumulate toward this limit over the admission.
Key Considerations for Plan Selection
- CDL formulary for bronchodilators — is tiotropium and combination LABA/ICS on the formulary?
- Pulmonologist network access — essential for GOLD 2+ management
- AECOPD hospitalisation benefit — the most financially significant COPD event
- Home oxygen therapy — does your scheme fund home O2 concentrators? Critical for GOLD 4.
- Pulmonary rehabilitation — some schemes have formal programmes; others do not
- Smoking cessation support — varenicline or NRT coverage may be available
Sources
- GOLD (Global Initiative for Chronic Obstructive Lung Disease) Report 2024
- SA Thoracic Society COPD Guidelines 2022
- CMS PMB Regulation 8 — CDL: COPD
- SAHPRA SEP database — prices estimated; verification pending.
To see what your own plan pays, check your cover with AURA →
This page is general information about medical schemes. It is not medical advice: speak to a healthcare professional about your own treatment. Medical aid and gap cover advice is given by Eldon de Waal, a Supervised Representative of Approach Administration (FSP 23579).